phrykt

NovoCure Ltd (NVCR): who owns it and who trades it

As of Nov 16, 2026, NVCR insiders reported 20 open-market sales worth $3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was William F Doyle (Chair), with $933K. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling NovoCure

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NVCR

214 funds and institutions reported NVCR shares worth $1.6B at the end of Q2 2026, about 90% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) 90%Everyone else 10%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
BlackRock, Inc.11.6%
Soleus Capital Management, L.P.8.6%
Vanguard Portfolio Management LLC5.4%
Vanguard Capital Management LLC4.2%
Morgan Stanley3.9%
State Street Corp2.5%
Geode Capital Management, LLC2.4%
Wells Fargo & Company2.2%
Quantinno Capital Management LP1.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)17.37M15.00%$263M+2%
BlackRock, Inc.13.41M11.58%$203M+2%
Soleus Capital Management, L.P.9.91M8.56%$150M-6%
Vanguard Portfolio Management LLC6.27M5.42%$95M+0%
Vanguard Capital Management LLC4.90M4.23%$74.3M+5%
Morgan Stanley4.52M3.90%$68.5M-0%
State Street Corp2.87M2.47%$43.4M+12%
Geode Capital Management, LLC2.80M2.42%$42.4M+11%
Wells Fargo & Company2.53M2.18%$38.3M-14%
Quantinno Capital Management LP2.22M1.92%$33.7M-11%
Renaissance Technologies LLC1.95M1.69%$29.6M+26%
JPMorgan Chase & Co1.67M1.44%$25.9M–
Healthcare of Ontario Pension Plan Trust Fund1.39M1.20%$21M+91%
Palo Alto Investors LP1.28M1.11%$19.4MNo change
Nuveen, LLC1.23M1.06%$18.7M+25%
Jacobs Levy Equity Management, Inc1.16M1.01%$17.6M-13%
Empowered Funds, LLC1.15M1.00%$17.5M–
AQR Capital Management LLC1.10M0.95%$16.7M+301%
Dimensional Fund Advisors LP1.09M0.94%$16.5M+14%
D. E. Shaw & Co., Inc.1.02M0.88%$15.5M+58%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NVCR insiders reported $0 of open-market purchases and $3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$3M
20 trades, 8 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 12, 2026

Purchases and sales by month

$1.9M$1.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026Christoph BrackmannCFOSale7,343$12.86$94.4KForm 4
Nov 9, 2026Mukund ParavasthuChief Operating OfficerSale3,079$12.86$39.6KForm 4
Nov 2, 2026Michal Nath PuriChief Human Resources OfSale660$13.24$8.7KForm 4
Jun 4, 2026Frank X LeonardCEOSale34,273$17.93$615KForm 4
Jun 2, 2026Gabriel LeungDirectorSale2,945$15.77$46.4KForm 4
Mar 5, 2026Mukund ParavasthuChief Operating OfficerSale43,246$13.77$595KForm 4
Mar 4, 2026Nicolas LeupinFormer Chief Medical OffSale1,100$13.31$14.6KForm 4
Mar 4, 2026Uri WeinbergChf Medical and InnovatiSale6,412$13.31$85.3KForm 4
Mar 4, 2026Frank X LeonardCEOSale5,607$13.31$74.6KForm 4
Mar 4, 2026Mukund ParavasthuChief Operating OfficerSale5,377$13.31$71.6KForm 4
Mar 3, 2026William F DoyleChairSale21,330$13.43$286KForm 4
Mar 3, 2026William F DoyleChairSale50,557$12.79$647KForm 4
Mar 2, 2026Uri WeinbergChf Medical and InnovatiSale3,272$13.33$43.6KForm 4
Mar 2, 2026Mukund ParavasthuChief Operating OfficerSale408$13.49$5.5KForm 4
Mar 2, 2026Frank X LeonardCEOSale7,232$13.49$97.6KForm 4
Feb 27, 2026Uri WeinbergChf Medical and InnovatiSale7,461$13.84$103KForm 4
Feb 27, 2026Michal Nath PuriChief Human Resources OfSale1,441$13.66$19.7KForm 4
Feb 27, 2026Mukund ParavasthuChief Operating OfficerSale1,555$13.66$21.2KForm 4
Feb 27, 2026Nicolas LeupinFormer Chief Medical OffSale1,029$13.66$14.1KForm 4
Feb 27, 2026Frank X LeonardCEOSale9,734$13.66$133KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
William F DoyleExecutive Chairman, Director–$933KMar 3, 2026
Frank X LeonardChief Executive Officer–$920KJun 4, 2026
Mukund ParavasthuChief Operating Officer–$733KNov 9, 2026
Uri WeinbergChf Medical and Innovation Ofr–$232KMar 4, 2026
Christoph BrackmannChief Financial Officer–$94.4KNov 9, 2026
Gabriel LeungDirector–$46.4KJun 2, 2026
Nicolas LeupinFormer Chief Medical Officer–$28.7KMar 4, 2026
Michal Nath PuriChief Human Resources Officer–$28.4KNov 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NVCR short interest

High short interest. 11.0% of NVCR shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 51%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.91M NVCR shares were sold short, 11.0% of the shares outstanding, up 0.7% from the report before. At the average daily volume of 2.14M shares, buying them all back would take about 6.0 trading days (days to cover).

Shares short, % of all shares

11.0%May 15Oct 3011.6%

Days to cover

6.0May 15Oct 3012.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.91M11.05%+1%2.14M6.0
Oct 15, 202612.82M11.01%+15%1.66M7.7
Sep 30, 202611.16M9.59%-5%1.11M10.1
Sep 15, 202611.80M10.13%+9%1.03M11.5
Aug 31, 202610.79M9.27%+18%1.41M7.6
Aug 14, 20269.17M7.87%-10%1.10M8.4
Jul 31, 202610.14M8.71%-12%2.07M4.9
Jul 15, 202611.46M9.89%-4%1.53M7.5
Jun 30, 202611.88M10.26%+23%1.92M6.2
Jun 15, 20269.65M8.33%+5%1.62M6.0
May 29, 20269.15M7.90%+7%1.32M6.9
May 15, 20268.54M7.37%+23%1.99M4.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

NovoCure company events

NovoCure filed 19 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementShared information with investors. Filing
  2. Oct 29, 2026ResultsReleased financial results. Filing
  3. Oct 1, 2026AnnouncementShared information with investors. Filing
  4. Sep 9, 2026LeadershipTimothy Scannell, a current director of NovoCure Limited, has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026. Filing
  5. Sep 1, 2026AnnouncementIn mid-August 2026, NovoCure Limited through a subsidiary, became aware of unauthorized access to some of its information systems. Filing
  6. Jul 23, 2026ResultsReleased financial results. Filing
  7. Jun 30, 2026AnnouncementShared information with investors. Filing
  8. Jun 18, 2026AnnouncementShared information with investors. Filing
  9. Jun 5, 2026LeadershipNovoCure Limited held its annual general meeting of shareholders. Filing
  10. Apr 30, 2026ResultsReleased financial results. Filing
  11. Apr 24, 2026LeadershipAmended an earlier report. Of the Initial Form 8-K. This Amendment provides a description of the compensation of Frank Leonard in connection with his appointment as Chief Executive Officer effective as of December 1, 2025. Filing
  12. Apr 9, 2026LeadershipNovoCure Limited, through one of its affiliates, modified the compensation of Uri Weinberg, M.D., Ph.D., a named executive officer of the Company, in connection with his appointment as Chief Medical Officer in addition to his role as Chief Innovation Officer of the Company. Filing
  13. Mar 26, 2026AnnouncementShared information with investors. Filing
  14. Feb 26, 2026ResultsReleased financial results. Filing
  15. Feb 24, 2026AnnouncementShared information with investors. Filing
  16. Feb 11, 2026AnnouncementShared information with investors. Filing
  17. Feb 5, 2026AnnouncementShared information with investors. Filing
  18. Jan 12, 2026ResultsReleased financial results. Filing
  19. Dec 1, 2025LeadershipResignation of Chief Executive Officer; Transition of Chief Financial Officer; Resignation of Chief Operating Officer On November 24, 2025, by mutual agreement, Ashley Cordova, Director and Chief Executive Officer of NovoCure Limited resigned as a member of the Board of Directors of NovoCure… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

NovoCure financials

Famous investors that hold NVCR

6 of the 50 well-known investors we track reported holding NVCR in their latest 13F filing. The largest position is Jim Simons's, worth $33.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.12M$33.8M0.0%+8%
Steve Cohen · Point72 Asset ManagementQ3 2026607,780$9.7M0.0%-24%
Ken Griffin · Citadel AdvisorsQ3 2026445,382$7.1M0.0%+183%
Paul Tudor Jones · Tudor Investment CorpQ3 2026400,060$6.4M0.0%+49%
Israel Englander · Millennium ManagementQ3 2026120,794$1.9M0.0%-57%
Ray Dalio · Bridgewater AssociatesQ3 202629,806$475K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NVCR in the last 120 days.

FiledHolderFormStake
Nov 9, 2026Soleus Capital Master Fund, L.P.13G/A8.1%
Nov 9, 2026Soleus Capital Master Fund, L.P.13G/A8.1%

Questions about NovoCure Ltd (NVCR) stock

Who owns the most NVCR stock?

The largest reported owner of NovoCure Ltd (NVCR) is FMR LLC (Fidelity), with 15.0% of the company. In total, 214 funds and institutions reported holding NVCR at the end of Q2 2026, together about 90% of the shares. See the largest owners.

Are NVCR insiders buying or selling?

In the last 12 months, NVCR insiders reported no open-market purchases and 20 sales worth $3M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in NVCR?

As of Oct 30, 2026, 12.91M NVCR shares were sold short, 11.0% of the shares outstanding, up 0.7% from the report before. At the average daily volume of 2.14M shares, buying them all back would take about 6.0 trading days (days to cover). See the history.

Which famous investors hold NVCR?

6 of the 50 well-known investors we track reported NVCR in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $33.8M. See all holders.

Executive pay

NovoCure's chief executive was paid a total of $1.5M for the year ended Dec 31, 2024, up 1% from $1.5M the year before. In the last 12 months, NovoCure's executives and directors bought no stock on the open market and sold $3M.

Chief executive, total pay$1.5MYear ended Dec 31, 2024. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$796KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$5.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.